Stella Ogake, MD
Pulmonary Disease · Columbus, OHNPI 1326468695
Payments from drug & device makers
Across 31 payments — averaging $110.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$2K
- Amgen$485
- AstraZeneca$356
- Genentech USA, Inc.$100
- Olympus America Inc.$59
- Johnson & Johnson$27
- plus $13 from 1 others
What the payments were for
- Travel & lodging$1,86655%
- Food & beverage$1,44642%
- Education$1003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 11 | $2,373 |
| Amgen | 7 | $485 |
| AstraZeneca | 8 | $356 |
| Genentech USA, Inc. | 1 | $100 |
| Olympus America Inc. | 1 | $59 |
| Johnson & Johnson | 2 | $27 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- superDimension$1,910
- TEZSPIRE$236
How this compares
$3,412 in reported general payments places this provider in the 55th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 18 | $289,887 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $31,718 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $9,984 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,431 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $1,371 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $950 |
| Fluticasone Propionate | 21 | $460 |
| Azithromycin | 15 | $123 |
| Montelukast Sodium | 12 | $42 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Columbus
- Edward CordascoColumbus$8M
- Brian ZenoColumbus$2.9M
- Roy St JohnColumbus$1.9M
- Nitin BhattColumbus$876K
- Matthew ExlineColumbus$386K
- Christian GhattasColumbus$286K
- Alberto ReveloColumbus$232K
- Derrick HermanColumbus$213K
- James FaganColumbus$179K
- Todd AstorColumbus$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.